Population
Children and adolescents with essential hypertension
Design
Review
Authors
Loading...
Expands labeled options for pediatric hypertension; leaves open efficacy and safety data for older agents.
This review highlights the increase in pediatric antihypertensive drug trials driven by regulatory incentives, while emphasizing the ongoing need for data on older, commonly prescribed medications.
Chu et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: